Savara (SVRA)
NASDAQ:SVRA
SVRA Stock Chart & Stats
$5.14
$0.04(1.15%)
At close: 4:00 PM EST
$5.14
$0.04(1.15%)
Day’s Range― - ―
52-Week Range$1.89 - $7.01
Previous CloseN/A
Volume189.20K
Average Volume (3M)1.79M
Market Cap
$1.05B
Enterprise Value$1.03B
Total Cash (Recent Filing)$235.70M
Total Debt (Recent Filing)$29.91M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 07, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding204,657,500
10 Day Avg. Volume2,642,326
30 Day Avg. Volume1,792,158
Financial Highlights & Ratios
PEG Ratio-1.08
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-774.62
Enterprise Value/Ebitda-8.45
Forecast
1Y Price Target
$10.25Price Target Upside99.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$16.55M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And Key Opinion Leader SupportPhase 3 results published in leading medical journals and endorsements from key opinion leaders highlight strong, durable efficacy and easy administration, supporting confidence in clinical adoption if approved.
Commercial Preparedness And Diagnostic ExpansionA launch-ready commercial infrastructure combined with a simple finger‑prick antibody test that uncovers underdiagnosed cases should enable efficient patient identification and targeted specialty sales uptake.
Regulatory ProgressFDA decision to forgo an Advisory Committee and to grant Priority Review reduces headline-driven uncertainty and increases the likelihood of a timely regulatory decision.
Bears Say
Liquidity And Funding UncertaintyHigh cash burn and an unclear cash runway could necessitate additional financing, creating execution risk and potential dilution that may hinder commercialization plans.
Manufacturing And Inspection RiskApproval continues to hinge on satisfactory chemistry, manufacturing and controls reviews and facility inspections, which could trigger late-stage regulatory delays or remediation requirements.
Reimbursement And Patient Access BarriersPersistent insurance denials and high out‑of‑pocket costs for off‑label alternatives indicate the potential for payer resistance that could limit patient access and commercial uptake even after approval.
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $1.89 and its highest was $7.00 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $1.05B.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is May 07, 2026 which is in 37 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Mar 13, 2026. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.119 by -$0.011.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.14.
How many shares outstanding does Savara have?
Savara has 204,657,500 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.119. Following the earnings report the stock price went down -1.316%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.25 (99.42% Upside)
$10.25 (99.42% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 9.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.89%
12-Months-Change
Fundamentals
Return on Equity
-84.01%
Trailing 12-Months
Asset Growth
19.05%
Trailing 12-Months
Company Description
Savara
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
SVRA Stock 12 Month Forecast
Average Price Target
$10.25
▲(99.42% Upside)
Technical Analysis
Ownership Overview
2.97% Insiders
7.18% Mutual Funds
72.77% Other Institutional Investors
7.57% Public Companies and
Individual Investors